ABEO Abeona Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ABEO

Price (delayed)

$2.71

Market cap

$46.55M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$18.56

Enterprise value

$43.77M

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis ...

Highlights
The company's gross profit rose by 45% YoY
The revenue is up by 45% year-on-year
Abeona Therapeutics's debt has increased by 35% YoY but it has decreased by 2.8% QoQ
Abeona Therapeutics's equity has shrunk by 81% YoY and by 23% QoQ
Abeona Therapeutics's net income has shrunk by 58% YoY and by 2.9% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://abeonatherapeutics.com
Peers: MRK

Key stats

What are the main financial stats of ABEO
Market
Shares outstanding
17.18M
Market cap
$46.55M
Enterprise value
$43.77M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.05
Price to sales (P/S)
4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.07
Earnings
Revenue
$4.35M
EBIT
-$84.51M
EBITDA
-$79.75M
Free cash flow
-$61.51M
Per share
EPS
-$18.56
Free cash flow per share
-$9.58
Book value per share
$2.59
Revenue per share
$0.68
TBVPS
$6.04
Balance sheet
Total assets
$38.76M
Total liabilities
$23.35M
Debt
$8.29M
Equity
$15.41M
Working capital
$12.9M
Liquidity
Debt to equity
0.54
Current ratio
2.02
Quick ratio
1.95
Net debt/EBITDA
0.03
Margins
EBITDA margin
-1,835%
Gross margin
100%
Net margin
-1,961.6%
Operating margin
-1,939.3%
Efficiency
Return on assets
-163.2%
Return on equity
-301%
Return on invested capital
-310.8%
Return on capital employed
-323%
Return on sales
-1,944.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABEO stock price

How has the Abeona Therapeutics stock price performed over time
Intraday
11.52%
1 week
13.39%
1 month
20.44%
1 year
834.48%
YTD
-12.01%
QTD
-12.01%

Financial performance

How have Abeona Therapeutics's revenue and profit performed over time
Revenue
$4.35M
Gross profit
$4.35M
Operating income
-$84.28M
Net income
-$85.25M
Gross margin
100%
Net margin
-1,961.6%
Abeona Therapeutics's net income has shrunk by 58% YoY and by 2.9% QoQ
The operating income has decreased by 46% YoY but it has increased by 6% from the previous quarter
The company's gross profit rose by 45% YoY
The revenue is up by 45% year-on-year

Growth

What is Abeona Therapeutics's growth rate over time

Valuation

What is Abeona Therapeutics stock price valuation
P/E
N/A
P/B
1.05
P/S
4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.07
ABEO's EPS is down by 30% year-on-year
Abeona Therapeutics's equity has shrunk by 81% YoY and by 23% QoQ
The price to book (P/B) is 48% lower than the 5-year quarterly average of 2.0 and 13% lower than the last 4 quarters average of 1.2
ABEO's P/S is 97% below its 5-year quarterly average of 133.4 and 56% below its last 4 quarters average of 9.0
The revenue is up by 45% year-on-year

Efficiency

How efficient is Abeona Therapeutics business performance
The company's return on invested capital has shrunk by 199% YoY
Abeona Therapeutics's return on equity has shrunk by 59% QoQ
The company's return on assets fell by 41% QoQ
ABEO's ROS is down by 19% year-on-year and by 3.6% since the previous quarter

Dividends

What is ABEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABEO.

Financial health

How did Abeona Therapeutics financials performed over time
The company's total assets is 66% higher than its total liabilities
The company's total assets has shrunk by 67% YoY and by 13% QoQ
ABEO's total liabilities is down by 41% YoY and by 5% QoQ
Abeona Therapeutics's debt is 46% lower than its equity
Abeona Therapeutics's equity has shrunk by 81% YoY and by 23% QoQ
Abeona Therapeutics's debt has increased by 35% YoY but it has decreased by 2.8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.